Tonix Pharm Holdings (TNXP)

$12.66 0.00 (N/A)
Market Cap 217.13M
Revenue (ttm) 13.11M
Net Income (ttm) -124.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -946.00%
Debt to Equity Ratio 0.00
Volume 188,100
Avg Vol 537,490
Day's Range N/A - N/A
Shares Out 17.15M
Stochastic %K 57%
Beta 1.69
Analysts Strong Sell
Price Target $42.40

Company Profile

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company d...

Industry: Biotechnology
Sector: Healthcare
Phone: 862 799 8599
Address:
200 Connell Drive, Suite 3100, Berkeley Heights, United States
StockJayC
StockJayC Aug. 19 at 2:12 PM
$TNXP So it seems, everything I am posting - the opposite is happening... Seth you watching the forum after my emails huh...?
0 · Reply
tratuein
tratuein Aug. 19 at 2:10 PM
$TNXP quién pudiera tener $MRNA , ellos sí que sabem vender la noticia y que la acción suba
0 · Reply
AliThePoorMan
AliThePoorMan Aug. 19 at 1:51 PM
$TNXP let's go
0 · Reply
Mstrong87
Mstrong87 Aug. 19 at 1:46 PM
$TNXP you probably have a lot of experience with that don’t you …it would explain your lack of math skills 😂😂🤡🤡🚀🚀🥳🥳
0 · Reply
4edddfw
4edddfw Aug. 19 at 1:37 PM
$TNXP 13 now or never let's do itn
0 · Reply
TheUnmaker
TheUnmaker Aug. 19 at 1:36 PM
$TNXP $PFE $IOVA
0 · Reply
TOOKPROFITS
TOOKPROFITS Aug. 19 at 1:28 PM
$TNXP Seth is like a meth head that has a $1000 a day habit but only pan handles $200 a day
0 · Reply
Stino715pro
Stino715pro Aug. 19 at 1:22 PM
$TNXP Jugger do you have the new Numbers? 👍
0 · Reply
NX19
NX19 Aug. 19 at 1:20 PM
$TNXP
0 · Reply
JustAguysOpinion
JustAguysOpinion Aug. 19 at 1:14 PM
$TNXP
0 · Reply
Latest News on TNXP
Tonix Pharmaceuticals Holding Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 11, 2026, 1:30 PM EDT - 7 days ago

Tonix Pharmaceuticals Holding Transcript: Canaccord Genuity's 46th Annual Growth Conference

Tonix Pharmaceuticals price target raised to $27 from $25 at Raymond James

2026-08-10T17:55:08.000Z - 8 days ago

Tonix Pharmaceuticals price target raised to $27 from $25 at Raymond James

Tonix Pharmaceuticals Holding Earnings Call Transcript: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 9 days ago

Tonix Pharmaceuticals Holding Earnings Call Transcript: Q2 2026

Tonix Pharmaceuticals Holding Earnings release: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 9 days ago

Tonix Pharmaceuticals Holding Earnings release: Q2 2026

Tonix Pharmaceuticals Holding Quarterly report: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 9 days ago

Tonix Pharmaceuticals Holding Quarterly report: Q2 2026

Tonix Pharmaceuticals Holding Slides: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 9 days ago

Tonix Pharmaceuticals Holding Slides: Q2 2026

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Aug 10, 2026, 7:00 AM EDT - 9 days ago

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 5, 2026, 7:00 AM EDT - 14 days ago

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

Tonix Pharmaceuticals receives Type C meeting minutes from FDA for TNX-4800

2026-08-03T11:56:09.000Z - 16 days ago

Tonix Pharmaceuticals receives Type C meeting minutes from FDA for TNX-4800

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

Aug 3, 2026, 7:00 AM EDT - 16 days ago

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

Tonix Pharmaceuticals Holding Slides: Investor presentation

Aug 3, 2026, 7:00 AM EDT - 16 days ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

Jul 27, 2026, 7:00 AM EDT - 23 days ago

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

Tonix Pharmaceuticals Holding Slides: Corporate presentation

Jul 20, 2026, 7:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Holding Slides: Corporate presentation

Tonix Pharmaceuticals Holding Slides: Investor presentation

Jul 16, 2026, 8:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

Jul 15, 2026, 9:05 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

Tonix Pharmaceuticals announces managed Medicare agreement for Tonmya

2026-07-13T11:15:17.000Z - 5 weeks ago

Tonix Pharmaceuticals announces managed Medicare agreement for Tonmya

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

Jul 13, 2026, 7:00 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

Tonix Pharmaceuticals Holding Slides: Investor presentation

Jul 1, 2026, 8:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Tonix Pharmaceuticals enrolls first patient in HORIZON study

2026-06-29T11:40:14.000Z - 7 weeks ago

Tonix Pharmaceuticals enrolls first patient in HORIZON study

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

Jun 29, 2026, 7:25 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

Tonix Pharmaceuticals initiated with a Strong Buy at Raymond James

2026-06-24T20:36:04.000Z - 7 weeks ago

Tonix Pharmaceuticals initiated with a Strong Buy at Raymond James

Tonix Pharmaceuticals Holding Slides: Investor presentation

Jun 15, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

Jun 11, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

Tonix Pharmaceuticals secures second commercial agreement for Tonmya

2026-06-08T11:14:39.000Z - 2 months ago

Tonix Pharmaceuticals secures second commercial agreement for Tonmya

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Jun 8, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Tonix Pharmaceuticals Holding Slides: Investor presentation

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Tonix presents data from analysis of opioid use in adults with fibromyalgia

2026-05-28T21:29:12.000Z - 2 months ago

Tonix presents data from analysis of opioid use in adults with fibromyalgia

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 28, 2026, 4:30 PM EDT - 2 months ago

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Tonix Pharmaceuticals publishes TNX-1500 data in Journal of Clinical Immunology

2026-05-27T13:00:38.000Z - 3 months ago

Tonix Pharmaceuticals publishes TNX-1500 data in Journal of Clinical Immunology

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

May 27, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

Tonix Pharmaceuticals Holding Slides: Investor presentation

May 27, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Tonix Pharmaceuticals presents data from analysis of adults with fibromyalgia

2026-05-26T11:57:59.000Z - 3 months ago

Tonix Pharmaceuticals presents data from analysis of adults with fibromyalgia

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

May 26, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

Tonix Pharmaceuticals Holding Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 1:35 PM EDT - 3 months ago

Tonix Pharmaceuticals Holding Transcript: RBC Capital Markets Global Healthcare Conference 2026

Tonix Pharmaceuticals Holding Slides: 2nd Richard Slayman Clinical Xenotransplantation Workshop presentation

May 17, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Slides: 2nd Richard Slayman Clinical Xenotransplantation Workshop presentation

Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026

Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

May 12, 2026, 4:30 PM EDT - 3 months ago

Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

Tonix Pharmaceuticals reports Q1 EPS ($2.93) vs. ($2.84) last year

2026-05-11T23:47:32.000Z - 3 months ago

Tonix Pharmaceuticals reports Q1 EPS ($2.93) vs. ($2.84) last year

Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights

May 11, 2026, 4:30 PM EDT - 3 months ago

Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights

Tonix Pharmaceuticals Holding Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Quarterly report: Q1 2026

Tonix Pharmaceuticals Holding Earnings release: Q1 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Earnings release: Q1 2026

Tonix Pharmaceuticals secures commercial payer coverage for Tonmya

2026-05-07T04:37:07.000Z - 3 months ago

Tonix Pharmaceuticals secures commercial payer coverage for Tonmya

Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients

May 6, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients

Tonix Pharmaceuticals initiated with a Buy at TD Cowen

2026-05-04T09:45:07.000Z - 3 months ago

Tonix Pharmaceuticals initiated with a Buy at TD Cowen

Tonix Pharmaceuticals says on track to initiate Phase 2 study of TNX-4800

2026-04-29T15:52:42.000Z - 3 months ago

Tonix Pharmaceuticals says on track to initiate Phase 2 study of TNX-4800

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University

Apr 29, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

Apr 23, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

Tonix Pharmaceuticals publishes Tonmya study data findings

2026-04-15T11:14:23.000Z - 4 months ago

Tonix Pharmaceuticals publishes Tonmya study data findings

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

Apr 15, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

Tonix Pharmaceuticals Holding Slides: Investor presentation

Apr 7, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Tonix Pharmaceuticals presents TNX-4800 data, to initiate adaptive field study

2026-03-31T11:25:26.000Z - 5 months ago

Tonix Pharmaceuticals presents TNX-4800 data, to initiate adaptive field study

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

Mar 31, 2026, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

Tonix Pharmaceuticals Holding Slides: Corporate presentation

Mar 31, 2026, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Holding Slides: Corporate presentation

Tonix Pharmaceuticals Holding Proxy statement: Proxy filing

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Holding Proxy statement: Proxy filing

Tonix Pharmaceuticals doses first patient in TNX-1900 study

2026-03-26T11:30:11.000Z - 5 months ago

Tonix Pharmaceuticals doses first patient in TNX-1900 study

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

Mar 26, 2026, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

Tonix Pharmaceuticals Holding Slides: Conference presentation

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Holding Slides: Conference presentation

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026

Mar 23, 2026, 4:32 PM EDT - 5 months ago

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026

Tonix Pharmaceuticals Holding Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Holding Proxy statement: Proxy filing

Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026

Mar 18, 2026, 4:58 PM EDT - 5 months ago

Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026

Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 17, 2026, 4:35 PM EDT - 5 months ago

Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 12, 2026, 5:30 PM EDT - 5 months ago

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Tonix Pharmaceuticals Holding Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Holding Earnings release: Q4 2025

Tonix Pharmaceuticals Holding Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Holding Annual report: Q4 2025

Tonix Pharmaceuticals Holding Transcript: Life Sciences Virtual Investor Forum

Mar 11, 2026, 1:00 PM EDT - 5 months ago

Tonix Pharmaceuticals Holding Transcript: Life Sciences Virtual Investor Forum

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 9, 2026, 4:30 PM EDT - 5 months ago

Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 9, 2026, 4:30 PM EDT - 5 months ago

Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Tonix Pharmaceuticals Holding Slides: Investor presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

Mar 5, 2026, 4:15 PM EST - 5 months ago

Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

Tonix Pharmaceuticals Holding Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 11:10 AM EST - 5 months ago

Tonix Pharmaceuticals Holding Transcript: TD Cowen 46th Annual Health Care Conference

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting

Mar 3, 2026, 4:30 PM EST - 6 months ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

Mar 3, 2026, 6:00 AM EST - 6 months ago

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

Feb 25, 2026, 7:00 AM EST - 6 months ago

Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Jan 30, 2026, 7:00 AM EST - 7 months ago

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

Jan 6, 2026, 7:00 AM EST - 8 months ago

Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

Dec 29, 2025, 7:57 AM EST - 8 months ago

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Dec 29, 2025, 7:45 AM EST - 8 months ago

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University

Dec 16, 2025, 7:00 AM EST - 8 months ago

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

Dec 9, 2025, 7:00 AM EST - 9 months ago

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Nov 24, 2025, 7:00 AM EST - 9 months ago

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

Nov 17, 2025, 7:00 AM EST - 9 months ago

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

Tonix Pharmaceuticals Holding Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 10:00 AM EST - 9 months ago

Tonix Pharmaceuticals Holding Transcript: Stifel 2025 Healthcare Conference

Tonix Pharmaceuticals Holding Slides: FY 2025

Nov 13, 2025, 10:00 AM EST - 9 months ago

Tonix Pharmaceuticals Holding Slides: FY 2025

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 10, 2025, 4:15 PM EST - 10 months ago

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Tonix Pharmaceuticals Holding Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Tonix Pharmaceuticals Holding Earnings release: Q3 2025

Tonix Pharmaceuticals Holding Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Tonix Pharmaceuticals Holding Quarterly report: Q3 2025

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference

Nov 6, 2025, 7:00 AM EST - 10 months ago

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Nov 4, 2025, 7:00 AM EST - 10 months ago

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

Oct 28, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Oct 27, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Oct 22, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Oct 21, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Oct 17, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation

Oct 14, 2025, 7:00 AM EDT - 11 months ago

Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Oct 9, 2025, 7:00 AM EDT - 11 months ago

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

StockJayC
StockJayC Aug. 19 at 2:12 PM
$TNXP So it seems, everything I am posting - the opposite is happening... Seth you watching the forum after my emails huh...?
0 · Reply
tratuein
tratuein Aug. 19 at 2:10 PM
$TNXP quién pudiera tener $MRNA , ellos sí que sabem vender la noticia y que la acción suba
0 · Reply
AliThePoorMan
AliThePoorMan Aug. 19 at 1:51 PM
$TNXP let's go
0 · Reply
Mstrong87
Mstrong87 Aug. 19 at 1:46 PM
$TNXP you probably have a lot of experience with that don’t you …it would explain your lack of math skills 😂😂🤡🤡🚀🚀🥳🥳
0 · Reply
4edddfw
4edddfw Aug. 19 at 1:37 PM
$TNXP 13 now or never let's do itn
0 · Reply
TheUnmaker
TheUnmaker Aug. 19 at 1:36 PM
$TNXP $PFE $IOVA
0 · Reply
TOOKPROFITS
TOOKPROFITS Aug. 19 at 1:28 PM
$TNXP Seth is like a meth head that has a $1000 a day habit but only pan handles $200 a day
0 · Reply
Stino715pro
Stino715pro Aug. 19 at 1:22 PM
$TNXP Jugger do you have the new Numbers? 👍
0 · Reply
NX19
NX19 Aug. 19 at 1:20 PM
$TNXP
0 · Reply
JustAguysOpinion
JustAguysOpinion Aug. 19 at 1:14 PM
$TNXP
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 19 at 1:05 PM
I know nothing!!! $PHAR $PHVS $TNXP $ALT
1 · Reply
alphonns
alphonns Aug. 19 at 1:04 PM
$TNXP https://www.stocktitan.net/sec-filings/TNXP/8-k-tonix-pharmaceuticals-holding-corp-reports-material-event-7f171b70fdaf.html
0 · Reply
WARBUD
WARBUD Aug. 19 at 12:50 PM
$TNXP🐂
0 · Reply
Joe676
Joe676 Aug. 19 at 12:35 PM
$TNXP
0 · Reply
auris
auris Aug. 19 at 12:13 PM
$TNXP
0 · Reply
Jinberg
Jinberg Aug. 19 at 11:19 AM
$TNXP
0 · Reply
StockJayC
StockJayC Aug. 19 at 10:53 AM
$TNXP Seth as interim CMO... Who's the new interim CEO whilst he takes on the CMO role or maybe just replacement CEO?
0 · Reply
ACMTrader
ACMTrader Aug. 19 at 10:50 AM
$TNXP 💎💎🚀
0 · Reply
TheUnmaker
TheUnmaker Aug. 19 at 10:33 AM
$TNXP
0 · Reply
AliThePoorMan
AliThePoorMan Aug. 19 at 10:02 AM
$TNXP Seth should step down.
0 · Reply
Stockeye2
Stockeye2 Aug. 19 at 9:18 AM
$TNXP 💎🚀
0 · Reply
Oldmoneycashhoney
Oldmoneycashhoney Aug. 19 at 8:09 AM
$TNXP bad news on tonix again
1 · Reply